{"id":2517,"date":"2026-02-11T14:04:31","date_gmt":"2026-02-11T13:04:31","guid":{"rendered":"https:\/\/clearorg.eu\/?p=2517"},"modified":"2026-02-11T14:04:31","modified_gmt":"2026-02-11T13:04:31","slug":"cosmetic-exfoliant-regulation-aha-bha-pha-eu-uk-usa","status":"publish","type":"post","link":"https:\/\/clearorg.eu\/en\/cosmetic-exfoliant-regulation-aha-bha-pha-eu-uk-usa\/","title":{"rendered":"Exfoliants in cosmetics &#8211; what do the regulations say?"},"content":{"rendered":"<p style=\"text-align: center;\"><strong>Hydroxy acids<\/strong>, including <strong>AHAs, BHAs, and PHAs<\/strong>, are <strong>exfoliating agents<\/strong> that have been widely used in cosmetic formulations for several decades to improve skin texture and radiance. Their well-established efficacy goes hand in hand with sensitivity <strong>safety considerations<\/strong> (irritation, photosensitisation) and regulatory approaches that vary by region.<\/p>\n<p style=\"text-align: center;\">This article reviews the <strong>regulatory frameworks in the European Union, the United Kingdom, and the United States, <\/strong>with the aim of providing a clearer understanding of these issues.<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>What&#8217;s behind these acronyms?<\/strong><\/h4>\n<p>&nbsp;<\/p>\n<p><strong>AHAs<\/strong> are the most common. The term refers to <strong>Alpha-Hydroxy Acids <\/strong>and includes, in particular, <strong>glycolic acid<\/strong> and<strong> lactic acid<\/strong>. They are water-soluble and therefore act primarily on the skin&#8217;s surface, where they exfoliate the outermost layer of the epidermis and promote cell renewal.<\/p>\n<p>&nbsp;<\/p>\n<p>Within the <strong>BHA<\/strong> (<strong>Beta Hydroxy Acids<\/strong>) family, the principal compound is <strong>salicylic acid<\/strong>. These are lipid-soluble and can penetrate the skin&#8217;s pores, which contributes to their exfoliating, comedolytic, and &#8220;anti-inflammatory\u201d properties.<\/p>\n<p>&nbsp;<\/p>\n<p>Finally, <strong>PHAs (Polyhydroxy Acids) <\/strong>include <strong>gluconic acid, gluconolactone,<\/strong> and <strong>lactobionic acid<\/strong>. They act as humectants by binding water in the epidermis, thereby enhancing hydration. They also provide similar effects to those of AHAs.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>What the texts say&#8230;.<\/strong><\/h4>\n<p>&nbsp;<\/p>\n<h5><strong>AHA<\/strong><\/h5>\n<p><u>In the European Union<\/u><\/p>\n<p>For the use of AHAs in the EU, it is necessary to go beyond Regulation (EC) No 1223\/2009 on cosmetic products and rely on the opinions issued by the independent expert committee, the <strong>SCCS<\/strong> (Scientific Committee on Consumer Safety), to determine permitted levels of use and conditions of use (pH, concentration, sensitive populations).<\/p>\n<p>Only the two most common ones have been subject to an <strong>evaluation<\/strong> (published in 2000 and confirmed in 2004), which concludes that:<\/p>\n<ul>\n<li><strong>Glycolic acid<\/strong> may be used safely at a maximum concentration of 4% and at a pH \u2265 3.8<\/li>\n<li><strong>Lactic acid<\/strong> may be used safely at a maximum concentration of 2.5% and at a pH \u2265 5.0.<\/li>\n<\/ul>\n<p>It is also recommended to:<\/p>\n<ul>\n<li>avoid exposure to the sun,<\/li>\n<li>use adequate sun protection,<\/li>\n<li>avoid contact with the eyes.<\/li>\n<\/ul>\n<p><strong>\u00a0<\/strong><\/p>\n<p><u>In the United Kingdom <\/u><\/p>\n<p>Nothing has been published about this class of ingredients since Brexit (2020).<\/p>\n<p>In the absence of an official UK position on the subject, it is generally assumed that British toxicologists continue to cite the SCCS advice as a scientific benchmark.<\/p>\n<p>&nbsp;<\/p>\n<p><u>In the United States<\/u><\/p>\n<p><strong>Particular caution is required with respect to claims associated with products containing AHAs<\/strong> : for example, skin-lightening products are classified as <strong>OTC<\/strong> (Over The Counter<em>)<\/em> drugs.<\/p>\n<p>The FDA has issued guidance stating that over-the-counter cosmetic products may contain up to 10% <strong>glycolic and lactic acids<\/strong> and have a pH \u2265 3.5.<br \/>\nThey must also be formulated with an SPF (Sun Protection Factor), and the label must bear a clear statement recommending the use of appropriate sun protection (\u201c<strong>Sunburn Alert<\/strong>\u201d).<\/p>\n<p>Furthermore, in the <strong>states of New York and California<\/strong>, <strong>bills to prohibit<\/strong> the sale of certain products containing these ingredients to individuals under 18 were introduced in 2025.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<h5><strong>BHA (Salicylic acid)<\/strong><\/h5>\n<p><u>In the European Union<\/u><\/p>\n<p>Salicylic acid is regulated under Annex III (entry 98) and Annex V (entry 3) of Regulation (EC) No 1223\/2009.<\/p>\n<p>The SCCS was recently mandated (January 2026) to assess its overall exposure.<\/p>\n<p>&nbsp;<\/p>\n<p><u>In the United Kingdom <\/u><\/p>\n<p>Following its evaluation by the SAG-CS in January 2022, the UK authorities added this substance to Annex III (entry 98) and restricted its use in cosmetic products (not as a preservative).<\/p>\n<p>&nbsp;<\/p>\n<p><u>In the United States<\/u><\/p>\n<p>Salicylic acid is considered an active ingredient in anti-acne and anti-dandruff products, which are classified as both <strong>OTC<\/strong> drugs rather than cosmetics<em>. <\/em>Therefore, as with AHAs, particular <strong>attention must be paid to the product&#8217;s claims<\/strong> if the intention is to remain within the cosmetics category.<\/p>\n<p>Salicylic acid was re-evaluated by the CIR in 2025, which concluded that products containing this ingredient are safe under the customary conditions and concentrations of use; the risk of photosensitisation was dismissed, and the associated recommendations are therefore no longer deemed necessary.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<h5><strong>PHA<\/strong><\/h5>\n<p>PHAs are <strong>not listed <\/strong>as prohibited or restricted products by Europe, the United Kingdom, or the United States. Their use must be deemed safe within the framework of the product\u2019s overall safety assessment.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>&nbsp;<\/p>\n<h4><strong>Key points to bear in mind when developing an exfoliating product containing one of these ingredients<\/strong><\/h4>\n<p>&nbsp;<\/p>\n<ul>\n<li><strong>Comply with the concentrations and pH values recommended<\/strong> by scientific advice or imposed by applicable regulations<\/li>\n<li>Conduct a comprehensive <strong>toxicological assessment <\/strong>and test the <strong>tolerance<\/strong> of the finished product when in use<\/li>\n<li>Include any necessary <strong>precautions for use<\/strong> (SPF use, photosensitisation, etc.)<\/li>\n<li>Check that your product is not classified as an <strong>OTC<\/strong> drug in the USA<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>CLEAR <\/strong>can support you throughout the development of your cosmetics. Do not hesitate to <a href=\"https:\/\/clearorg.eu\/en\/contact\/\">contact us!<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><em><u>Sources\u00a0: <\/u><\/em><\/p>\n<p><em>Egli\u00a0C,\u00a0Min\u00a0M,\u00a0Afzal\u00a0N,\u00a0Sivamani\u00a0RK.\u00a0<\/em><em>The hydroxy acids: where have we been and\u00a0what&#8217;s new?\u00a0Dermatol Rev.\u00a02023;\u00a04:\u00a0260-267.\u00a0<\/em><a href=\"https:\/\/doi.org\/10.1002\/der2.217\"><strong><em>doi:10.1002\/der2.217<\/em><\/strong><\/a><\/p>\n<p><em>Almeman AA. Evaluating the Efficacy and Safety of Alpha-Hydroxy Acids in Dermatological Practice: A Comprehensive Clinical and Legal Review. Clin Cosmet Investig Dermatol. 2024 Jul 16;17:1661-1685. doi: 10.2147\/CCID.S453243 <\/em><\/p>\n<p><a href=\"https:\/\/ec.europa.eu\/health\/ph_risk\/committees\/sccp\/documents\/out121_en.pdf\"><em>https:\/\/ec.europa.eu\/health\/ph_risk\/committees\/sccp\/documents\/out121_en.pdf<\/em><\/a><\/p>\n<p><a href=\"https:\/\/ec.europa.eu\/health\/ph_risk\/committees\/sccp\/documents\/out284_en.pdf\"><em>https:\/\/ec.europa.eu\/health\/ph_risk\/committees\/sccp\/documents\/out284_en.pdf<\/em><\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/cosmetics\/cosmetic-ingredients\/alpha-hydroxy-acids\"><em>https:\/\/www.fda.gov\/cosmetics\/cosmetic-ingredients\/alpha-hydroxy-acids<\/em><\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids\"><em>https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-labeling-cosmetics-containing-alpha-hydroxy-acids<\/em><\/a><\/p>\n<p><a href=\"https:\/\/www.cir-safety.org\/sites\/default\/files\/ahas.pdf\"><em>https:\/\/www.cir-safety.org\/sites\/default\/files\/ahas.pdf<\/em><\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/cosmetics\/cosmetic-ingredients\/beta-hydroxy-acids\"><em>https:\/\/www.fda.gov\/cosmetics\/cosmetic-ingredients\/beta-hydroxy-acids<\/em><\/a><\/p>\n<p><a href=\"https:\/\/cir-reports.cir-safety.org\/view-attachment\/?id=f8f3e083-2ca8-b5b4-b338-aa3ca6da8825\"><em>https:\/\/cir-reports.cir-safety.org\/view-attachment\/?id=f8f3e083-2ca8-b5b4-b338-aa3ca6da8825<\/em><\/a><\/p>\n<p><a href=\"https:\/\/health.ec.europa.eu\/document\/download\/4bf9186a-f05c-4930-b54c-19b26a41bd1a_en?filename=sccs2022_q_047.pdf\"><em>https:\/\/health.ec.europa.eu\/document\/download\/4bf9186a-f05c-4930-b54c-19b26a41bd1a_en?filename=sccs2022_q_047.pdf<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hydroxy acids, including AHAs, BHAs, and PHAs, are exfoliating agents that have been<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":5,"featured_media":2521,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[231,232,204,99,230,228,229,114,233,101,227],"_links":{"self":[{"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/posts\/2517"}],"collection":[{"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/comments?post=2517"}],"version-history":[{"count":3,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/posts\/2517\/revisions"}],"predecessor-version":[{"id":2530,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/posts\/2517\/revisions\/2530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/media\/2521"}],"wp:attachment":[{"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/media?parent=2517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/categories?post=2517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clearorg.eu\/en\/wp-json\/wp\/v2\/tags?post=2517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}